Skip to main content

Table 2 Inflammatory biomarkers in relationship to clinical features (cross sectional studies)

From: Inflammatory biomarkers in patients with sciatica: a systematic review

Study Age (yr) Duration (months) Source Technique Marker Clin O Ass
Piperno [16] 40 + − 13 20 + −26 serum Degradation PhosA2 VAS no
Brisby [17] N 92 (5–390)a serum CSF ELISA Il-8 VAS r = −0,48
Sugimor [18] 26.4 (16–39) N serum Latex agl hsCRP JOA r = −0,583
Cheng [19] 44 (30–72) N serum ELISA Il-17 VAS r = 0,458
Xue [20] 52 (21–70) N serum NP Biopsy mRNA qPCR Il-21 VAS r = 0,809
Peng [21] 34.2 (+ − 5.8)b 4.5 (1–22) serum Western blot CX3CL1 VAS r = 0, 393
serum Western blot CX3CL1 JOA r = − 0,342
serum Western blot CCL2 VAS r = 0, 360
serum Western blot CCL2 JOA r = −0,375
Palada [22] 41.13 (15–65) >  1 month serum mRNA qPCR Il-6 VAS r = 0,380
CSF mRNA qPCR Il-8 VAS r = 0,395
serum mRNA qPCR MCP1 VAS r = 0,515
  1. Ass association, Clin O clinical outcome, CSF cerebrospinal fluid, ELISA enzyme linked serum assay, IL interleukin, JOA Japanese orthopedic association score, Latex agl latex agglutination, NP nucleus pulposus, qPCR quantitative polymerase chain reaction, VAS visual analogue scale, Yr years
  2. adays
  3. bVAS > 7